IL90427A - Peptide-containing pharmaceutical compositions having use for treatment of neuropsychiatric deficits - Google Patents

Peptide-containing pharmaceutical compositions having use for treatment of neuropsychiatric deficits

Info

Publication number: IL90427A
Authority: IL; Israel
Prior art keywords: thr; ala; formula; cys; linear peptide
Prior art date: 1988-05-27

Application number

IL9042789A

Other languages

English (en)

Original Assignee

Us Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-05-27

Filing date

1989-05-26

Publication date

1994-10-07

1989-05-16 Priority claimed from US07/352,313 external-priority patent/US5063206A/en

1989-05-26 Application filed by Us Health filed Critical Us Health

1994-10-07 Publication of IL90427A publication Critical patent/IL90427A/en

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 61
239000008194 pharmaceutical composition Substances 0.000 title claims description 11
230000006735 deficit Effects 0.000 title description 4
239000000203 mixture Substances 0.000 claims abstract description 10
206010027175 memory impairment Diseases 0.000 claims abstract description 6
208000026139 Memory disease Diseases 0.000 claims abstract description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
150000002148 esters Chemical class 0.000 claims description 9
150000001408 amides Chemical class 0.000 claims description 8
150000001413 amino acids Chemical class 0.000 claims description 8
125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 3
CUTPSEKWUPZFLV-WISUUJSJSA-N Thr-Cys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(O)=O CUTPSEKWUPZFLV-WISUUJSJSA-N 0.000 claims 4
239000000935 antidepressant agent Substances 0.000 claims 3
230000001519 thymoleptic effect Effects 0.000 claims 3
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 2
208000031886 HIV Infections Diseases 0.000 claims 2
208000037357 HIV infectious disease Diseases 0.000 claims 2
239000003085 diluting agent Substances 0.000 claims 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
208000020016 psychiatric disease Diseases 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 abstract description 26
230000027455 binding Effects 0.000 abstract description 8
210000004027 cell Anatomy 0.000 abstract description 8
201000004681 Psoriasis Diseases 0.000 abstract description 6
241000725303 Human immunodeficiency virus Species 0.000 abstract description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
208000035475 disorder Diseases 0.000 abstract description 4
208000019022 Mood disease Diseases 0.000 abstract description 2
238000012360 testing method Methods 0.000 description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
230000000694 effects Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
239000000243 solution Substances 0.000 description 5
108010071384 Peptide T Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
230000001149 cognitive effect Effects 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
108090000189 Neuropeptides Proteins 0.000 description 2
-1 Thr amide Chemical class 0.000 description 2
108070000030 Viral receptors Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000003902 lesion Effects 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
230000001755 vocal effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
208000017667 Chronic Disease Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
102100021696 Syncytin-1 Human genes 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
KQDPSIMTNJSDOM-UHFFFAOYSA-N benzene styrene Chemical compound C1=CC=CC=C1.C1=CC=CC=C1.C=CC1=CC=CC=C1 KQDPSIMTNJSDOM-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000003925 brain function Effects 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
229940105847 calamine Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229920006026 co-polymeric resin Polymers 0.000 description 1
239000011280 coal tar Substances 0.000 description 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
206010013932 dyslexia Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229910052864 hemimorphite Inorganic materials 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
201000003723 learning disability Diseases 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000036651 mood Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000003557 neuropsychological effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
IWHCAJPPWOMXNW-LYKMMFCUSA-N peptide t Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 IWHCAJPPWOMXNW-LYKMMFCUSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
210000003370 receptor cell Anatomy 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
210000004761 scalp Anatomy 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000010792 warming Methods 0.000 description 1
235000014692 zinc oxide Nutrition 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1
CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

IL9042789A 1988-05-27 1989-05-26 Peptide-containing pharmaceutical compositions having use for treatment of neuropsychiatric deficits IL90427A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US19987388A	1988-05-27	1988-05-27
US28555988A	1988-12-16	1988-12-16
US07/352,313 US5063206A (en)	1988-12-16	1989-05-16	Compositions having use as treatment of neuropsychiatric deficits

Publications (1)

Publication Number	Publication Date
IL90427A true IL90427A (en)	1994-10-07

Family

ID=27394077

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9042789A IL90427A (en)	1988-05-27	1989-05-26	Peptide-containing pharmaceutical compositions having use for treatment of neuropsychiatric deficits

Country Status (8)

Country	Link
EP (1)	EP0415999B1 (ja)
JP (2)	JPH0618777B2 (ja)
AT (1)	ATE168698T1 (ja)
AU (1)	AU620107B2 (ja)
CA (1)	CA1336677C (ja)
DE (1)	DE68928752T2 (ja)
IL (1)	IL90427A (ja)
WO (1)	WO1989012067A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6242564B1 (en) *	1986-06-03	2001-06-05	Candace B. Pert	Treatment of tropical spastic paresis with peptide T
US5189022A (en) *	1988-05-27	1993-02-23	The United States Of America As Represented By The Secretary Of Health And Human Services	Composition for the treatment of chronic fatigue syndrome
DK31991D0 (da) *	1991-02-25	1991-02-25	Carlbiotech Ltd As	Peptid og farmaceutisk praeparat indeholdende et saadant peptid
ATE194495T1 (de) *	1992-03-27	2000-07-15	Advanced Immunit T Inc	T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose
US6011014A (en) *	1992-03-27	2000-01-04	Advanced Immunit, Inc.	Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
RU2130317C1 (ru) *	1992-03-27	1999-05-20	Пептайд Текнолоджи Лимитед	Линейные или циклические пептиды, их применение, способ лечения
ES2220915T3 (es) *	1993-09-24	2004-12-16	Advanced Immuni T, Inc.	Peptidos lineales y ciclicos para el tratamiento o prevencion de la enfermedad de crohn y/o colitis ulcerosa.
DE69433763T2 (de) *	1993-09-24	2005-04-14	Advanced Immuni T, Inc.	Lineare und cyklische peptide zur behandlung oder verhinderung von ekzem und dermatitis
US7085486B2 (en)	2002-08-27	2006-08-01	Pentax Corporation	Lens barrel incorporating a rotatable ring
JP2004085932A (ja)	2002-08-27	2004-03-18	Pentax Corp	ズームレンズ鏡筒の繰出カム機構及び繰出カム機構
US7058293B2 (en)	2002-08-27	2006-06-06	Pentax Corporation	Optical element retracting mechanism for a retractable lens
JP3863829B2 (ja)	2002-08-27	2006-12-27	ペンタックス株式会社	ズームレンズ鏡筒の繰出カム機構及び繰出カム機構

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5921613A (ja) *	1982-07-28	1984-02-03	Takeda Chem Ind Ltd	直腸投与製剤
AU7544987A (en) *	1986-06-03	1988-01-11	Pert, C.B.	Small peptides which inhibit binding to t-4 receptors
ATE96450T1 (de) *	1986-06-03	1993-11-15	Us Commerce	Kleine peptide, die die bindung an t-4-rezeptoren inhibieren und als immunogene wirken.
US4804651A (en) *	1987-06-09	1989-02-14	Board Of Regents, The University Of Texas System	Methods and compositions for the treatment of psoriasis
PT90657B (pt) *	1988-05-27	1995-03-01	Ortho Pharma Corp	Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora

1989
- 1989-05-25 WO PCT/US1989/002205 patent/WO1989012067A1/en not_active Ceased
- 1989-05-25 AU AU36936/89A patent/AU620107B2/en not_active Expired
- 1989-05-25 EP EP89906251A patent/EP0415999B1/en not_active Expired - Lifetime
- 1989-05-25 AT AT89906251T patent/ATE168698T1/de not_active IP Right Cessation
- 1989-05-25 DE DE68928752T patent/DE68928752T2/de not_active Expired - Fee Related
- 1989-05-25 JP JP1506059A patent/JPH0618777B2/ja not_active Expired - Lifetime
- 1989-05-26 IL IL9042789A patent/IL90427A/en unknown
- 1989-05-29 CA CA000600999A patent/CA1336677C/en not_active Expired - Fee Related
1993
- 1993-09-16 JP JP5230549A patent/JP3011837B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU620107B2 (en)	1992-02-13
JPH0618777B2 (ja)	1994-03-16
JP3011837B2 (ja)	2000-02-21
JPH03502928A (ja)	1991-07-04
AU3693689A (en)	1990-01-05
WO1989012067A1 (en)	1989-12-14
JPH06228001A (ja)	1994-08-16
DE68928752T2 (de)	1998-12-03
DE68928752D1 (de)	1998-08-27
EP0415999A4 (en)	1991-10-16
EP0415999A1 (en)	1991-03-13
EP0415999B1 (en)	1998-07-22
CA1336677C (en)	1995-08-15
ATE168698T1 (de)	1998-08-15

Legal Events

Date	Code	Title
1999-11-30	KB	Patent renewed
2003-07-06	KB	Patent renewed
2007-07-06	KB	Patent renewed

Publication	Publication Date	Title
SWANSON et al.	1962	Myoclonus—a report of 67 cases and review of the literature
US5063206A (en)	1991-11-05	Compositions having use as treatment of neuropsychiatric deficits
DE69311427T2 (de)	1998-02-12	Synthetische Polypeptide als Inhibitoren von HIV-1
IL90427A (en)	1994-10-07	Peptide-containing pharmaceutical compositions having use for treatment of neuropsychiatric deficits
WO1997031002A9 (en)	1997-10-30	Fused pyrrolo(2,3-c)carbazole-6-ones which potentiate activity of gamma interferon
ATE87484T1 (de)	1993-04-15	Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
AU663875B2 (en)	1995-10-26	Compositons for the treatment of chronic fatigue syndrome
McComas et al.	1971	Motoneurone dysfunction in patients with hemiplegie atrophy
FI96865C (fi)	1996-09-10	Menetelmä terapeuttisesti käyttökelpoisen, olennaisesti puhtaan polypeptidin valmistamiseksi
Naftchi	1982	Functional restoration of the traumatically injured spinal cord in cats by clonidine
IL105822A (en)	1999-11-30	Pharmaceutical products useful for treatment of tropical spastic paresis
US5534495A (en)	1996-07-09	Treatment of non-HIV neuropathic pain syndromes
US5248667A (en)	1993-09-28	Method of treating psoriasis using synthetic peptide compositions
RU2290197C2 (ru)	2006-12-27	Фармацевтическое средство для лечения вич-инфекции, содержащая его композиция и способы его применения
EP1075270B1 (en)	2005-06-15	Short peptide for treatment of neurological degenerative diseases
CA2465349A1 (en)	2003-06-12	Transdermal drug for the treatment of neural paralysis and dysfunction
ES2222625T3 (es)	2005-02-01	Peptido t y peptidos asociados destinados al tratamiento de la inflamacion incluyendo la esclerosis multiple.
RU2288716C2 (ru)	2006-12-10	Нейротропные аналоги такролимуса
RS40804A (sr)	2006-12-15	Postupak za reagovanje alkaloida i upotreba proizvoda reakcije za dobijanje medikamenata
Lebedyeva et al.	2015	Ionic conjugates of lidocaine and sweeteners as better tasting local anesthetics for dentistry
WO1999018123A1 (fr)	1999-04-15	Utilisation des bloqueurs des canaux potassium neuronaux et lymphocytaires dans le traitement des maladies neurologiques d'origine immunitaire
Bennett	1946	The introduction of curare into clinical medicine: present and potential usefulness
CN120303285A (zh)	2025-07-11	一种多肽及其应用
JP2000500156A (ja)	2000-01-11	ヒルから得られる抗ウイルス性単離物